Online citations, reference lists, and bibliographies.
← Back to Search

Evidence‐based (S3) Guidelines For The Treatment Of Psoriasis Vulgaris

A. Nast, I. Kopp, M. Augustin, K. Banditt, W. Boehncke, M. Follmann, M. Friedrich, M. Huber, C. Kahl, J. Klaus, J. Koza, I. Kreiselmaier, Johannes Mohr, U. Mrowietz, H. Ockenfels, H. Orzechowski, J. Prinz, K. Reich, T. Rosenbach, S. Rosumeck, M. Schlaeger, G. Schmid‐Ott, M. Sebastian, V. Streit, T. Weberschock, B. Rzany
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract  Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1 to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, patient surveys have revealed lack of satisfaction with the efficacy of available treatments and a high rate of non‐compliance.
This paper references
10.1016/S0190-9622(03)00792-8
Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis.
M. Grundmann-Kollmann (2004)
10.2340/0001555576353356
Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis.
I. Hagemann (1996)
10.1046/j.1365-2133.1998.02124.x
Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study
Mrowietz (1998)
Comparison of two therapeutic regimens, continuous monotherapy and intermittent therapy, for long-term maintenance of remission of psoriasis with cyclosporin A
J. Nakayama (1996)
10.1001/ARCHDERM.1984.01650450051017
Psoralens and UV-A and UV-B twice weekly for the treatment of psoriasis.
K. M. Diette (1984)
10.1056/NEJMOA030002
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
M. Lebwohl (2003)
10.1067/MJD.2000.107940
Tazarotene plus UVB phototherapy in the treatment of psoriasis.
J. Koo (2000)
10.1016/S0190-9622(96)80148-4
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994.
M. Menter (1996)
10.3109/09546639109086777
Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone diacetate ointment for psoriasis - a multicentre, randomized, double-blinded study
Tsu‐Yi Chuang (1991)
10.1046/j.1468-3083.2003.00519_12.x
Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin
K. Agnew (2003)
Handbook of Psoriasis. 2
C Camisa (2004)
10.1111/j.1365-2133.2004.05986.x
Efficacy of once‐daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris
K. Kragballe (2004)
10.1159/000249273
Irritant potential of dithranol.
U. F. Haustein (1986)
10.1067/MJD.2003.417
The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
T. S. Housman (2003)
10.1002/j.1552-4604.1995.tb04131.x
Efficacy and Pharmacokinetics of Two Formulations of Cyclosporine A in Patients with Psoriasis
Cheryl A. Elder (1995)
10.1002/ART.10172
Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells.
S. Saijo (2002)
10.1056/NEJM199101313240501
Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial.
C. Ellis (1991)
10.1111/j.1600-0625.1992.tb00071.x
A reappraisal of the use of 5‐methoxypsoralen in the therapy of psoriasis
P. Calzavara-Pinton (1992)
10.1016/S0190-9622(00)90214-7
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis.
A. Gottlieb (2000)
10.1016/S0190-9622(96)90025-0
Interruption of long-term methotrexate treatment in psoriasis: evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate
E. Sherertz (1996)
10.1001/ARCHDERM.141.1.43
Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment.
C. Carroll (2005)
10.1111/j.1365-2133.1994.tb02901.x
Methotrexate revisited: effects of long‐term treatment in psoriasis
R. J. Dooren-Greebe (1994)
10.1067/MJD.2003.169
Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.
A. Freeman (2003)
10.1016/S0190-9622(98)70323-8
Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.
M. Lebwohl (1998)
10.1007/S10227-001-0031-Z
A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis
L. Green (2002)
Systemic therapy of psoriasis using methotrexate.
K. Smith (2000)
10.1016/S0190-9622(84)70188-5
Role of ultraviolet A in phototherapy for psoriasis.
K. M. Diette (1984)
10.1111/j.1365-2249.1994.tb06244.x
Elevated tumour necrosis factor‐alpha (TNF‐α) biological activity in psoriatic skin lesions
P. Ettehadi (1994)
Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics.
A. Nyfors (1978)
10.1001/ARCHDERM.134.9.1101
Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study.
I. Zonneveld (1998)
10.1080/00015550310022916
Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis.
E. Snellman (2004)
10.1001/ARCHDERM.1983.01650270025011
Topical steroids and UV radiation in psoriasis.
J. Petrozzi (1983)
Liver biopsy in methotrexate-treated psoriatics-a re-evalution.
H. Zachariae (1975)
10.3109/09546639809160546
A comparison of the efficacy and safety of the combination mometasone furoate 0.1 %/salicylic acid 5% ointment with each of its components in psoriasis
H. Katz (1998)
10.1067/MJD.2003.130
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis.
K. Papp (2003)
10.1016/S0190-9622(99)70008-3
A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis.
P. Gordon (1999)
10.1159/000063148
Topical Calcipotriol plus Oral Fumaric Acid Is More Effective and Faster Acting than Oral Fumaric Acid Monotherapy in the Treatment of Severe Chronic Plaque Psoriasis vulgaris
H. Gollnick (2002)
10.1067/MJD.2002.120454
Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study.
S. Feldman (2002)
10.1067/MJD.2001.112400
Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.
V. Ho (2001)
A randomized comparison of three conventional modes of treatment of psoriasis of the scalp.
Ross Sd (1981)
10.1111/j.1365-2133.2004.06070.x
Biological therapies in the systemic management of psoriasis: International Consensus Conference
W. Sterry (2004)
10.1001/ARCHDERM.1971.04000130035004
Methotrexate for psoriasis. A new therapeutic schedule.
G. Weinstein (1971)
10.1016/0163-8343(89)90036-4
A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients.
M. Gupta (1989)
10.1111/j.1365-2133.1995.tb06924.x
Laser treatment of psoriasis
G. Katugampola (1995)
10.1001/ARCHDERM.1982.01650170033018
The role of tar in Goeckerman therapy.
D. Belsito (1982)
10.1111/j.1365-2133.1975.tb06498.x
A prospective study of the effects of weekly oral methotrexate on liver biopsy
A. Warin (1975)
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
A. Gottlieb (2004)
10.1111/j.1365-2133.2005.06422.x
Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long‐term methotrexate: a multicentre audit and health economic analysis
R. Chalmers (2005)
10.1001/ARCHDERM.1992.01680160143028
The effect of flash lamp-pulsed dye laser on psoriasis.
S. M. Hacker (1992)
10.1046/j.1365-2133.2003.05153.x
Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines
N. Litjens (2003)
A new treatment of ichthyosis and other hyperkeratotic conditions.
G. Swanbeck (1968)
10.1034/j.1600-0781.2000.160502.x
Comparison of phototherapy two times and four times a week with low doses of narrow‐band ultraviolet B in Asian patients with psoriasis
V. Leenutaphong (2000)
10.1111/j.1365-2133.1980.tb06553.x
Methotrexate induced liver cirrhosis
H. Zachariae (1980)
10.1111/j.1365-2133.1992.tb00460.x
Bath‐water compared with oral delivery of 8‐methoxypsoralen PUVA therapy for chronic plaque psoriasis
P. C. Llins (1992)
10.1067/MJD.2001.117850
The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.
K. Papp (2001)
The impact of the frequency of short contact dithranol treatment.
M. Prins (2001)
10.1016/S0149-2918(97)80094-X
Mometasone furoate 0.1%-salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis.
R. S. Medansky (1997)
10.1046/j.1365-2133.1999.02974.x
A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology
Grassberger (1999)
10.1007/s001050050401
Das Wirkungs- und Sicherheitsprofil von Fumarsäureestern in der oralen Langzeittherapie bei schwerer therapieresistenter Psoriasis vulgaris Eine Untersuchung an 83 Patienten
P. Altmeyer (1996)
Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis.
A. Mussi (1997)
Dermatologie und Venerologie. 5. Aufl
O Braun-Falco
Randomized double-blind multicenter study comparing acitretin-PUVA and placebo-PUVA in the treatment of severe psoriasis
J H Saurat (1988)
Arzneimittelverordnungen. Im Auftrag der Arzneimittelkommission der Deutschen Ärzteschaft
Müller-Oerlinghausen
10.1001/ARCHDERM.1985.01660100077019
Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis.
R. Moy (1985)
10.1016/S0091-6749(96)70163-X
Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells.
W. Sperr (1996)
10.1046/j.1365-2133.2003.05433.x
Long‐term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis
J. Hoefnagel (2003)
10.1046/j.1365-2133.2001.04074.x
Calcitriol 3 µg g−1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study
J. Ring (2001)
10.1097/00000441-195102000-00009
THERAPEUTIC SUPPRESSION OF TISSUE REACTIVITY: II. Effect of Aminopterin in Rheumatoid Arthritis and Psoriasis
R. Gubner (1951)
10.1016/S0190-9622(98)70214-2
Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination.
P. Calzavara-Pinton (1998)
10.4049/jimmunol.167.9.4974
1α,25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4+ T Cells to Enhance the Development of Th2 Cells1
A. Boonstra (2001)
10.1016/S0190-9622(89)70071-2
Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis.
C. Nieboer (1989)
10.1111/j.1365-2133.1996.tb07608.x
Efficacy and safety of topical calcitriol (1,25‐dihydroxyvitamin D3) for the treatment of psoriasis
A. Pérez (1996)
Perorale Langzeitbehandlung der Psoriasis mit Fumarsäurederivaten
W Bayard (1987)
Cyclosporine versus etretinate: Italian multicentre comparative trial in severe psoriasis
A F Finzi (1993)
10.1111/j.1365-2230.1978.tb01512.x
A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis
D. Vella Briffa (1978)
10.1111/j.1346-8138.1988.tb03652.x
Combination of Photochemotherapy (PUVA) and Ultraviolet B (UVB) in the Treatment of Psoriasis Vulgaris
Y. Park (1988)
10.1046/J.1523-1747.2001.01159.X
Inhibition of dendritic cell differentiation by fumaric acid esters.
K. Zhu (2001)
10.1001/ARCHDERM.1979.04010090024017
Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate.
C. Hanke (1979)
10.1111/j.1468-3083.1998.tb00948.x
Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis
J. Austad (1998)
Efficacy and safety of oral cyclosporine A (CYA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis
C Laburte (1994)
10.1046/j.1365-2133.2002.04698.x
Combining lesional short‐contact dithranol therapy of psoriasis with a potent topical corticosteroid
O. Swinkels (2002)
10.1016/J.JAAD.2004.06.010
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
Carin H. Gribetz (2004)
10.1111/J.1523-1747.2003.12605.X
Dimethylfumarate is a potent inducer of apoptosis in human T cells.
F. Treumer (2003)
10.1016/S0733-8635(18)30045-7
Tars and anthralins.
A. Silverman (1995)
Management of guttate and generalized psoriasis vulgaris: prospective randomized study.
N. G. Caca-Biljanovska (2002)
10.1016/S0149-2918(00)83065-9
A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
L. Guenther (2000)
Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
Poulin Yp (1999)
10.1159/000080854
Efficacy of Treatment with Calcipotriol/Betamethasone Dipropionate Followed by Calcipotriol Alone Compared with Tacalcitol for the Treatment of Psoriasis vulgaris: A Randomised, Double-Blind Trial
J. Ortonne (2004)
10.1067/MJD.2002.120472
Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.
R. Schopf (2002)
European Handbook of Dermatological Treatments. 2. Aufl
A D Katsambas (2003)
10.1016/S0190-9622(99)80050-4
Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis.
J. Miller (1999)
10.1111/j.1365-2133.1992.tb00458.x
Inhibition of human monocyte functions by anthralin
U. Mrowietz (1992)
10.1046/j.1365-2133.1998.02319.x
A randomized, double‐blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis
Koo (1998)
10.1016/S0140-6736(81)92137-1
ORAL 8-METHOXYPSORALEN PHOTOCHEMOTHERAPY OF PSORIASIS: The European PUVA Study: a Cooperative Study among 18 European Centres
T. Henseler (1981)
10.1111/1523-1747.EP12461062
Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry.
W. Weston (1988)
10.1159/000252574
Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy.
A. Nyfors (1970)
10.1177/247553030208A00301
Definitions of Measures of Effect Duration for Psoriasis Treatments
K. Gordon (2002)
10.1016/0190-9622(91)70091-F
A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study.
H. Murray (1991)
10.1016/S0190-9622(94)70121-0
Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients.
P. Altmeyer (1994)
10.1111/j.1365-4362.1988.tb02429.x
Acitretin (Ro 10‐1670) in the Treatment of Severe Psoriasis
A. Ledo (1988)
10.1016/S0190-9622(82)70157-4
Combined methotrexate--ultraviolet B therapy in the treatment of psoriasis.
B. Paul (1982)
10.1111/j.1365-2133.1990.tb01481.x
Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis
P. Petzelbauer (1990)
10.1016/0190-9622(95)90189-2
Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.
G. Mahrle (1995)
10.1046/j.1365-2249.2003.02225.x
Pimecrolimus does not affect the differentiation, maturation and function of human monocyte‐derived dendritic cells, in contrast to corticosteroids
F. Kalthoff (2003)
10.1111/j.1365-2133.1992.tb00126.x
A multicentre, parallel‐group comparison of calcipotriol ointment and short‐contact dithranol therapy in chronic plaque psoriasis
J. Berth-Jones (1992)
10.1046/J.1365-2133.2001.04376.X
Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
S. Reitamo (2001)
10.1055/S-0028-1103898
[Legionnaires' disease. Clinical aspects, pathology, bacteriology and epidemiology].
Müller He (1979)
10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7
Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.
A. V. van Ede (2001)
Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
M. Berg (1994)
10.1016/S0190-9622(99)70112-X
Psoriasis causes as much disability as other major medical diseases.
S. Rapp (1999)
10.1111/j.1365-2230.1986.tb00457.x
Salicyclic acid gel for scalp psoriasis
S. Going (1986)
10.1007/S10227-001-0006-0
Betamethasone Valerate Foam for Treatment of Nonscalp Psoriasis
L. Stein (2001)
10.1111/j.1365-2133.1995.tb02754.x
Sequential liver biopsies during long‐term methotrexate treatment for psoriasis: a reappraisal
M. Boffa (1995)
10.1016/S0190-9622(08)80228-9
Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment.
D. N. Kolbach (1992)
10.1016/S0190-9622(98)70508-0
Methotrexate in psoriasis: consensus conference.
H. Roenigk (1998)
10.1038/357692A0
FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin
S. J. O'Keefe (1992)
10.1159/000248567
Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis.
J. Saurat (1988)
10.1016/J.MOLMED.2004.11.003
Dimethylfumarate for psoriasis: more than a dietary curiosity.
U. Mrowietz (2005)
10.1001/ARCHDERM.1997.03890480034005
Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B.
T. Coven (1997)
10.1067/MJD.2002.125075
Medium-dose 308-nm excimer laser for the treatment of psoriasis.
M. Trehan (2002)
10.1056/NEJM197412052912301
Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.
J. Parrish (1974)
10.1111/j.1468-3083.1997.tb00509.x
Dead sea bath salt for the treatment of psoriasis vulgaris: a double‐blind controlled study
S. Halevy (1997)
10.2340/00015555756569
Remission of ordinary psoriasis following a short clearance course of cyclosporin.
N. Levell (1995)
10.1111/j.1365-2133.1988.tb03224.x
Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis
J. Risteli (1988)
10.1046/j.1365-2133.2000.04713.x
Topical preparations for the treatment of psoriasis: a systematic review
J. Mason (2002)
10.1111/j.1365-2133.1994.tb02935.x
Efficacy and safety of oral cyclosporin A (CyA; Sandimmun®) for long‐term treatment of chronic severe plaque psoriasis
C. Laburte (1994)
[Acute toxic polyneuropathy following short-time hydroxyquinoline administration].
W. Müller (1979)
10.1111/j.1365-2133.1987.tb04920.x
Dithranol mediates pro‐oxidative inhibition of polymorphonuclear leukocyte migration and lymphocyte proliferation
R. Anderson (1987)
10.1111/j.1365-2133.1989.tb01406.x
A double‐blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis
J. Lauharanta (1989)
10.1111/j.0007-0963.2004.05739.x
Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities
P. Balasubramaniam (2004)
10.1016/S0190-9622(89)70154-7
Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study.
A. Finzi (1989)
10.1001/ARCHDERM.138.9.1221
The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review.
J. de Korte (2002)
10.1067/MJD.2003.103
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
G. Weinstein (2003)
10.1155/1996/213596
Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up.
D. Malatjalian (1996)
10.1007/s00105-005-0906-9
Psychosoziale Folgen der Psoriasis—eine empirische Studie über die Krankheitslast bei 3753 Betroffenen
G. Schmid‐Ott (2005)
10.1046/j.1365-4362.2001.01167.x
Investigator‐masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis
J. Koo (2001)
10.1056/NEJMOA021359
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
V. M. Heydendael (2003)
10.1001/ARCHDERM.1980.01640280049016
Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals.
J. Robinson (1980)
10.1002/EJI.1830260916
Selective stimulation of T helper 2 cytokine responses by the anti‐psoriasis agent monomethylfumarate
R. D. de Jong (1996)
10.1007/S10227-002-0114-5
The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp Regions
A. Gottlieb (2003)
10.1097/00006842-199809000-00020
Influence of a Mindfulness Meditation-Based Stress Reduction Intervention on Rates of Skin Clearing in Patients With Moderate to Severe Psoriasis Undergoing Photo Therapy (UVB) and Photochemotherapy (PUVA)
J. Kabat-Zinn (1998)
Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate.
H. Meffert (1989)
10.1046/j.1365-2133.2001.04355.x
A comparison of the effect of narrow‐band ultraviolet B in the treatment of psoriasis after salt‐water baths and after 8‐methoxypsoralen baths
W. Arnold (2001)
10.1111/j.1365-2133.2005.06306.x
Safety and efficacy study on etanercept in patients with plaque psoriasis
A. Costanzo (2005)
10.1159/000029933
Dithranol in a Cream Preparation: Disperse or Dissolve?
M. Prins (2000)
10.1007/BF01105083
Cyclosporin A, FK506 and dithranol alter tyrosine-specific protein phosphorylation in HaCaT keratinocytes
H. M. Ockenfels (2005)
10.1080/09546630310019346
Fumaric acid esters in the treatment of psoriasis: an Italian experience
I. Carboni (2004)
Psoriasis -auf einen Blick. 1. Aufl
E Christophers (2002)
10.1016/0190-9622(93)70069-6
Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis.
P. Duhra (1993)
10.1159/000018457
The Efficacy, Safety and Tolerance of Calcitriol 3 μg/g Ointment in the Treatment of Plaque Psoriasis: A Comparison with Short-Contact Dithranol
P. E. Hutchinson (2000)
10.1159/000247286
Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis.
A. Finzi (1993)
10.1046/j.1365-2133.1998.02400.x
The antipsoriatic agent dimethylfumarate immunomodulates T‐cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network
Ockenfels (1998)
10.1002/ART.20335
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
P. Mease (2004)
10.1016/J.JAAD.2004.09.029
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
C. Leonardi (2005)
10.1001/ARCHDERM.139.3.325
Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis.
T. Markham (2003)
10.1111/J.1600-0536.1994.TB01965.X
Intolerance and contact allergy to tar and dithranol in psoriasis
A. Burden (1994)
10.1080/09546630410023322
A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris
H. Torras (2004)
10.1067/MJD.2001.113448
Liver biopsies and methotrexate: a time for reconsideration?
R. Chalmers (2001)
Cyclosporine for plaquetype psoriasis. Results of a multidose, double-blind trial
C N Ellis (1991)
10.1016/S0190-9622(88)70086-9
Acitretin improves psoriasis in a dose-dependent fashion.
M. T. Goldfarb (1988)
10.1177/039463200401700321
Association of Cyclosporine and 311 nM UVB in the Treatment of Moderate to Severe Forms of Psoriasis: A New Strategic Approach
C. Franchi (2004)
Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis.
J. Decroix (2004)
10.1067/MJD.2003.307
Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.
A. Gottlieb (2003)
10.1016/S0190-9622(88)70198-X
Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.
H. Gollnick (1988)
10.1159/000249793
Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study.
A. Nyfors (1983)
10.1016/S0140-6736(88)91335-9
INTRALESIONAL INJECTION OF CYCLOSPORIN IN PSORIASIS
A. Powles (1988)
10.1200/JCO.1996.14.10.2769
Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors.
G. Rustin (1996)
10.1016/S0140-6736(00)04954-0
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
U. Chaudhari (2001)
10.1001/JAMA.290.23.3073
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
K. Gordon (2003)
10.1001/ARCHDERM.1989.01670210056007
The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment.
M. Newman (1989)
10.1111/j.1365-2133.1990.tb04192.x
Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis
A. Finlay (1990)
10.1016/S0002-9343(05)80060-9
Methotrexate and histologic hepatic abnormalities: a meta-analysis.
Q. Whiting-O'Keefe (1991)
10.1046/j.1365-4362.2000.00913.x
Psoralen–ultraviolet A therapy vs. psoralen–ultraviolet B therapy in the treatment of plaque‐type psoriasis: our experience with Fitzpatrick skin type IV
K. Khurshid (2000)
10.1159/000247323
Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis.
J. Shupack (1993)
10.1159/000065971
Calcipotriol Plus Short-Contact Dithranol: A Novel Topical Combination Therapy for Chronic Plaque Psoriasis
A. Monastirli (2002)
10.1016/S0190-9622(99)70362-2
Acitretin in combination with UVB or PUVA.
M. Lebwohl (1999)
10.1056/NEJMOA030409
Etanercept as monotherapy in patients with psoriasis.
C. Leonardi (2003)
10.1046/j.1365-2133.1998.02030.x
The effect of addition of calcipotriol ointment (50 μg/g) to acitretin therapy in psoriasis
Van De Kerkhof (1998)
10.1136/oem.29.2.188
Scrotal cancer in the north-west of England, 1962-68
W. R. Lee (1972)
10.1016/S0011-393X(05)80413-8
A comparative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris
Å. Svensson (1992)
[The practice guideline 'Photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis'].
P. I. Spuls (2004)
10.1111/j.1346-8138.2002.tb00321.x
A Novel Liposomal Formulation of Dithranol for Psoriasis: Preliminary Results
R. Agarwal (2002)
A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study.
K. Kragballe (1989)
10.1111/1523-1747.EP12274997
Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils.
J. Schröder (1985)
10.1067/MAI.2001.111850
Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis.
G. Schmid-Ott (2001)
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
A. Menter (2004)
10.1007/s004030050251
Influence of monomethylfumarate on monocytic cytokine formation – explanation for adverse and therapeutic effects in psoriasis?
K. Asadullah (1997)
10.1046/j.1365-2133.1999.02927.x
Tacrolimus ointment improves psoriasis in a microplaque assay
Remitz (1999)
10.1159/000210784
The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams.
S. de Mare (1988)
10.1046/j.1529-8019.2003.01622.x
Balneotherapy in dermatology
H. Matz (2003)
10.1016/S0190-9622(89)70085-2
Are topical corticosteroids useful in phototherapy for psoriasis?
J. S. Dover (1989)
with fumaric acid esters: results of a prospective multicentre study
10.1016/S0926-9959(97)00181-5
Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris.
F. Kokelj (1998)
10.1159/000017515
Depth Psychology-Founded Psychotherapy of Psoriatic Patients – Treatment of a Patient with Chronic Recidivating Psoriasis vulgaris
G. Schmid-Ott (2000)
10.1046/j.1365-2133.1996.35790.x
The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate‐induced hepatic damage in psoriasis patients
R. J. VANDOOREN‐GREEBE (1996)
10.1159/000248398
Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis.
P. Berbis (1989)
10.1046/j.1365-2133.2002.04967.x
Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double‐blind, vehicle‐controlled clinical trial
L. Guenther (2002)
10.2340/0001555574295297
The systemic effect of dithranol treatment in psoriasis.
M. Goodfield (1994)
10.1001/ARCHDERM.1979.04010070016013
Tar gel-phototherapy for psoriasis. Combined therapy with suberythemogenic doses of fluorescent sunlamp ultraviolet radiation.
P. Frost (1979)
10.1111/1523-1747.EP12319272
Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial.
A. Fleischer (1997)
10.1159/000066440
A New Calcipotriol/Betamethasone Dipropionate Formulation (DaivobetTM) Is an Effective Once-Daily Treatment for Psoriasis vulgaris
R. Kaufmann (2002)
10.1111/j.1365-2133.1984.tb07470.x
A randomized double‐blind comparison of PUVA‐etretinate and PUVA‐placebo in the treatment of chronic plaque psoriasis
S. Parker (1984)
10.1111/j.1365-4362.1992.tb02669.x
LIVER BIOPSY VERSUS ULTRASOUND IN METHOTREXATE‐TREATED PSORIASIS: A DECISION ANALYSIS
ARNAUD C. Verschuur (1992)
10.1159/000246849
Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis.
P. Calzavara-Pinton (1994)
10.1046/J.1087-0024.2003.09102.X
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.
R. Stern (2004)
10.1016/S0149-2918(98)80091-X
Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
J. Koo (1998)
10.2340/00015555733740
Down-regulation of epidermal growth factor receptors by dithranol.
L. Kemény (1993)
10.1006/BBRC.1997.6570
Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.
M. Vandermeeren (1997)
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthri
Z Ortiz
10.1016/S0140-6736(01)06179-7
Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study
I. Marcil (2001)
10.5694/j.1326-5377.1990.tb125127.x
The treatment of psoriasis
H. Rotstein (1990)
10.1001/ARCHDERM.141.1.31
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
A. Menter (2005)
10.1080/09546630305545
Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy
J. M. Camarasa (2003)
10.1046/j.1365-2133.2002.04622.x
A cognitive‐behavioural symptom management programme as an adjunct in psoriasis therapy
D. Fortune (2002)
10.1016/0092-8674(91)90124-H
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
J. Liu (1991)
10.1111/j.1468-3083.2004.01054.x
Psoriasis of the glans penis in a child successfully treated with ElidelR (pimecrolimus) cream
B. Amichai (2004)
10.7326/0003-4819-130-6-199903160-00004
Etanercept Therapy in Rheumatoid Arthritis
L. Moreland (1999)
10.1016/S0190-9622(94)70138-5
A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study.
R. M. Grossman (1994)
Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics.
H. Zachariae (1989)
Ergebnisse einer Cyclosporin-behandlung bei schwerer, chronischer Psoriasis vulgaris
R Engst (1989)
10.1046/j.1365-2133.1999.02766.x
Large increments in psoralen–ultraviolet A (PUVA) therapy are unsuitable for fair‐skinned individuals with psoriasis
Kirby (1999)
[Peroral long-term treatment of psoriasis using fumaric acid derivatives].
W. Bayard (1987)
10.1046/j.1365-2230.2000.00589.x
A comparison of bathwater and oral delivery of 8‐methoxypsoralen in PUVA therapy for plaque psoriasis
Cooper (2000)
10.1097/00007611-197811000-00009
Treatment of Psoriasis With 8‐Methoxypsoralen and Sunlight
D. Robertson (1978)
10.1159/000018309
Calcipotriol Cream Combined with Twice Weekly Broad-Band UVB Phototherapy: A Safe, Effective and UVB-Sparing Antipsoriatric Combination Treatment
C. Ramsay (2000)
10.1046/j.1365-2133.2000.03883.x
Acitretin is converted to etretinate only during concomitant alcohol intake
F. Grønhøj Larsen (2000)
10.1046/j.1365-4362.2002.01431.x
A randomized, double‐blind, placebo‐controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis
M. Lebwohl (2002)
10.1067/MJD.2000.108319
Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid.
M. Lebwohl (2000)
10.1080/09546630310021947
A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser
T. S. Housman (2004)
10.1046/j.1365-2133.1999.140S54018.x
Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis
Gollnick (1999)
10.1111/j.1610-0387.2005.05729.x
Cost‐of‐illness in patients with moderate and severe chronic psoriasis vulgaris in Germany
K. Berger (2005)
10.1159/000029819
Dithranol Embedded in Crystalline Monoglycerides Combined with Phototherapy (UVB): A New Approach in the Treatment of Psoriasis
M. Gerritsen (1998)
10.1016/S0140-6736(79)90820-1
COMPARISON OF PHOTOCHEMOTHERAPY AND DITHRANOL IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS
S. Rogers (1979)
The Hospital Anxiety and Depression Scale.
G. Huston (1987)
10.1046/J.1439-0353.2003.03615.X
Recommendations for phototherapy and photochemotherapy
E. Hölzle (2003)
10.2340/0001555577137141
Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.
H. Meffert (1997)
TL-01) phototherapy vs oral 8-methoxypsoralen-UV-A for the treatment of chronic plaque psoriasis
T Markham (2003)
10.1111/j.1365-2133.1995.tb02670.x
A comparison of twice‐weekly MPD‐PUVA and three times‐weekly skin typing‐PUVA regimens for the treatment of psoriasis
D. Buckley (1995)
10.1046/j.1365-4362.1999.00500.x
The role of salicylic acid in the treatment of psoriasis
M. Lebwohl (1999)
10.1016/S0190-9622(89)70138-9
Side-effect profile of acitretin therapy in psoriasis.
A. Gupta (1989)
10.1080/00015550310003791
Papular neutrophilic dermatosis and erythema elevatum diutinum following erythropoietin therapy in a patient with myelodysplastic syndrome.
E. Gubinelli (2003)
10.1046/J.1523-1747.2003.12040.X
Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
C. Paul (2003)
10.1159/000017504
Empfehlungen zur Erfassung von Lebensqualität in der Dermatologie
M. Augustin (2000)
10.1001/ARCHDERM.139.4.436
Efficacy of acitretin and commercial tanning bed therapy for psoriasis.
Christopher S Carlin (2003)
10.1006/PHRS.1996.0069
Climatotherapy of psoriasis and hypertension in elderly patients at the Dead-Sea.
A. Kushelevsky (1996)
10.1046/j.1365-2133.1998.02554.x
The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
Mrowietz (1998)
Nuclear factor of activated T cells (NFAT) as a molecular target for 1alpha,25-dihydroxyvitamin D3-mediated effects.
A. Takeuchi (1998)
10.1159/000057884
Safety and Efficacy of Combined High-Dose Treatment with Calcipotriol Ointment and Solution in Patients with Psoriasis
P. V. D. van de Kerkhof (2002)
The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis.
P. V. D. van de Kerkhof (1998)
Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis.
C. Orfanos (1979)
10.1046/j.1365-2230.2001.00870.x
Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis
M. Ameen (2001)
10.1159/000066425
Body-Weight-Independent Dosing of Cyclosporine Micro-Emulsion and Three Times Weekly Maintenance Regimen in Severe Psoriasis
D. Thąci (2002)
10.1111/j.1600-0536.1996.tb02199.x
Ultrasound description and quantification of irritant reactions induced by dithranol at different concentrations
M. Schiavi (1996)
10.1016/0167-5699(93)90061-O
The mechanisms of action of cyclosporin A in the treatment of psoriasis.
R. Wong (1993)
10.1111/1523-1747.EP12506317
The effect of topical fluocinonide ointment on phototherapy of psoriasis.
M. Levine (1982)
10.1111/j.1365-2230.1992.tb02161.x
The efficacy of methotrexate in psoriasis—a review of 40 cases
P. Collins (1992)
10.1016/J.JAAD.2004.02.021
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
A. Gottlieb (2004)
[Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study].
W. M. Nugteren-Huying (1990)
10.1016/S0190-9622(99)80057-7
Patients with psoriasis and their compliance with medication.
H. Richards (1999)
10.1016/S0190-9622(82)70005-2
Combined methotrexate-PUVA therapy in the treatment of psoriasis.
W. Morison (1982)
10.1111/1523-1747.EP12499901
Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro.
A. Gottlieb (1992)
10.1111/1523-1747.EP12512282
The effect of anthralin and its derivatives on epidermal cell kinetics.
L. B. Fisher (1975)
10.1159/000057974
Atopic Eczema Prevention Program in Childhood and Adolescence – a Model Project of the GermanGovernment
G. Schmid-Ott (2000)
Intralesional cyclosporin in psoriasis.
A. Powles (1989)
Salicylsäure zur topischen Anwendung. Bundesanzeiger 19.06
Anonymous (1990)
Treatment of Skin Disease. 1
M Lebwohl (2002)
10.1016/J.JACI.2004.03.021
Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis.
E. Schuller (2004)
10.1111/j.1365-2133.1989.tb01402.x
Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A
E. Higgins (1989)
10.1046/j.1365-2133.1996.d01-1035.x
Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease
G. J. Nevitt (1996)
10.1159/000012336
A Pilot Study of Hypnosis in the Treatment of Patients with Psoriasis
F. Tausk (1999)
10.1001/ARCHDERM.139.12.1627
A randomized trial of etanercept as monotherapy for psoriasis.
A. Gottlieb (2003)
10.1016/0190-9622(91)70089-K
Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone.
N. Lowe (1991)
10.1111/j.1365-2133.2003.05653.x
Optimizing the frequency of outpatient short‐contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within‐patient controlled trial
S. R. McBride (2003)
10.1080/00015550252948194
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris.
W. S. Douglas (2002)
10.1046/j.1365-2133.1999.02976.x
Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis
Clark (1999)



This paper is referenced by
Pharmakokinetik und Pharmakodynamik von Fumarsäureestern
Martin Rostami Yazdi (2008)
10.1007/s00105-010-1941-8
[Biologics. New drugs, new adverse reactions].
Joerg Christoph Prinz (2010)
10.1111/j.1468-3083.2012.04492.x
Efficacy of systemic therapies for moderate‐to‐severe psoriasis: a systematic review and meta‐analysis of long‐term treatment
T. C. Lucka (2012)
10.1016/j.jaad.2008.02.040
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
A. Gottlieb (2008)
Use of methotrexate in patients with psoriasis.
A. Kuhn (2010)
10.1038/jid.2010.164
Critical appraisal of quality of clinical practice guidelines for treatment of psoriasis vulgaris, 2006-2009.
J. Tan (2010)
10.1111/ijd.12842
Correlation between vascular endothelial growth factor and subclinical atherosclerosis in patients with psoriasis
M. Shahidi-Dadras (2016)
Psoriasis: Comorbidity and Treatment
M Wakkee (2010)
10.1159/000250826
Efficacy of a Single Educative Intervention in Patients with Chronic Plaque Psoriasis
V. Lora (2009)
10.1111/j.1365-2133.2008.08692.x
Knowledge, attitudes and use of the guidelines for the treatment of moderate to severe plaque psoriasis among Dutch dermatologists
M. Wakkee (2008)
10.1016/j.jaad.2008.12.032
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
A. Menter (2009)
10.1002/9781118661796.CH17
Treatment of plaque psoriasis
K. Kragballe (2014)
10.1016/S1578-2190(10)70638-7
[Commentary on European and British guidelines for the treatment of psoriasis].
L. Puig (2010)
10.1111/j.1440-0960.2011.00852.x
Pilot study on the acceptance of mobile teledermatology for the home monitoring of high‐need patients with psoriasis
J. Frühauf (2012)
10.7196/SAMJ.4015
Guideline on the management of psoriasis in South Africa.
N. Raboobee (2010)
10.1111/J.1610-0387.2009.07312.X
Evidence‐based (S3) guideline for the treatment of psoriasis vulgaris – Update: “Therapeutic options” and “Efalizumab”
A. Nast (2010)
10.1136/bmj.b5666
Managing comorbid disease in patients with psoriasis
W. Boehncke (2010)
10.1007/s13555-020-00409-4
Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature
Deepak M. W. Balak (2020)
10.1111/j.1600-0846.2011.00556.x
Targeted 307 nm UVB‐phototherapy in psoriasis. A pilot study comparing a 307 nm excimer light with topical dithranol
U. Wollina (2012)
10.1111/jdv.13542
Consensus document on the evaluation and treatment of moderate‐to‐severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology
E. Dauden (2016)
10.1111/J.1610-0379.2011.07680.SUPP.X
S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011
A. Nast (2011)
10.1007/s00105-008-1571-6
Möglichkeiten und Grenzen der Psoriasistherapie mit Biologics
A. Süß (2008)
10.1055/s-0030-1262432
[Comorbidities in psoriasis].
Peter Weisenseel (2010)
10.1007/978-1-4471-4432-8_22
Summary of Published Treatment Guidelines
V. Reeder (2014)
10.1016/S1578-2190(09)70086-1
[Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents].
L. Puig (2009)
10.1001/archdermatol.2009.375
Pilot study using teledermatology to manage high-need patients with psoriasis.
J. Frühauf (2010)
10.1016/S1578-2190(11)70782-X
Narrowband UV-B, Monochromatic Excimer Laser, and Photodynamic Therapy in Psoriasis: A Consensus Statement of the Spanish Psoriasis Group
J. Carrascosa (2011)
10.3238/arztebl.2009.0011
Psoriasis--new insights into pathogenesis and treatment.
U. Mrowietz (2009)
10.1016/j.jaad.2009.08.026
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.
A. Menter (2010)
10.1111/j.1610-0387.2009.07275.x
Three years after the publication of the German (S3) evidence based Psoriasis Guidelines – Was it worth the effort?
A. Nast (2009)
10.2165/11537470-000000000-00000
Treating Psoriasis with Etanercept in Italian Clinical Practice
A. Arcese (2010)
10.1001/archdermatol.2012.36
A patient decision aid for psoriasis based on current clinical practice guidelines.
J. Tan (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar